<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03205085</url>
  </required_header>
  <id_info>
    <org_study_id>2017-A00785-48</org_study_id>
    <nct_id>NCT03205085</nct_id>
  </id_info>
  <brief_title>Determinants of Right Heart Remodeling in Patients With CTEPH or PAH</brief_title>
  <acronym>PRINCEPT</acronym>
  <official_title>Determinants of Postoperative Right Heart Remodeling in Patients With Chronic Thrombo-Embolic Pulmonary Hypertension After Endarterectomy, or Pulmonary Arterial Hypertension After Lung Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Chirurgical Marie Lannelongue</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Chirurgical Marie Lannelongue</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Right heart failure is the main cause of morbi-mortality in patients with pulmonary&#xD;
      hypertension (PH), including patients of chronic thrombo-embolic pulmonary hypertension&#xD;
      (CTEPH) or pulmonary arterial hypertension (PAH) etiologies. Endarterectomy is an effective&#xD;
      treatment for patients with CTEPH to lower pulmonary pressure. Evidence of postoperative&#xD;
      right heart remodeling are contrasted according to the studies and determinants of right&#xD;
      heart failure are still unclear. Similarly, few evidence exists on right ventricular&#xD;
      remodeling after bilateral lung transplantation for patients with pulmonary arterial&#xD;
      hypertension (PAH). Recent evidence have supported the role of inflammation and immunity in&#xD;
      the pathophysiology of PAH . While several cytokines have been shown to predict survival ,&#xD;
      little is known on the implication of inflammation and immunity in postoperative Right&#xD;
      Ventricular failure in patients with PAH.&#xD;
&#xD;
      • The specific translational goal of this current project is to elucidate the role of immune&#xD;
      biomarkers in 6 months postoperative right heart adverse remodeling in patients with CTEPH or&#xD;
      PAH. We speculate that selected immune biomarkers (such as CXCL9, interleukin -18 or&#xD;
      interferon) and growth factors (such as HGF) are correlated with mid-term postoperative right&#xD;
      heart failure.&#xD;
&#xD;
      All consecutive adults with either CTEPH referred to our center for endarterectomy, or PAH&#xD;
      referred for lung transplantation, will be included, aiming for 150 CTEPH and 50 PAH. After&#xD;
      inclusion, patients will undergo assessment of right heart dimensions and function by cardiac&#xD;
      magnetic resonance imaging (MRI, including 4-Dimensions blood flow sequences) and 2D and 3D&#xD;
      trans-thoracic echocardiography (TTE), as well as immune panel analysis. All patients will&#xD;
      undergo as part of routine care right heart catheterization within a week after TTE and MRI&#xD;
      imaging. On the day of surgery, pulmonary pressure will be measured by right heart&#xD;
      catheterization monitoring (as part of routine care) in order to estimate the drop of&#xD;
      pressure and to adjust for the extent of endarterectomy for patients with CTEPH. TTE will&#xD;
      also be performed on the day of surgery if possible. At 7 days post-endarterectomy or&#xD;
      transplant, clinical outcomes will be collected and peripheral blood will be collected.&#xD;
      Patients will be prospectively follow-up for 6 months. Death, need for reintervention,&#xD;
      duration of vasopressor after surgery and number, duration and cause of readmission will be&#xD;
      recorded. At 6 months after surgery, all survivors will undergo the same biological sampling,&#xD;
      as well as an 4D MRI and a 2D and 3D TTE. Data of right heart catheterization at 6 months (as&#xD;
      part of routine care) will be collected as well.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 9, 2017</start_date>
  <completion_date type="Anticipated">July 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>right ventricular adverse remodeling</measure>
    <time_frame>6 months</time_frame>
    <description>postoperative right ventricular adverse remodeling, defined by increase above 10% in end-systolic right ventricular volume indexed on body surface area assessed by cardiac MRI.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Chronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>CTEPH PATIENTS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergoing pulmonary endarterectomy for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PAH PATIENTS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with pulmonary arterial hypertension (PAH) undergoing lung transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>magnetic resonance imaging</intervention_name>
    <description>assessment of right heart dimensions and function by cardiac magnetic resonance Imaging.</description>
    <arm_group_label>CTEPH PATIENTS</arm_group_label>
    <arm_group_label>PAH PATIENTS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>2D and 3D trans-thoracic echocardiography</intervention_name>
    <description>assessment of right heart dimensions and function by 2D and 3D trans-thoracic echocardiography</description>
    <arm_group_label>CTEPH PATIENTS</arm_group_label>
    <arm_group_label>PAH PATIENTS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <description>Blood samples for assays of immune inflammatory biomarkers (InterLeukin-18, CXCL9 or interferon</description>
    <arm_group_label>CTEPH PATIENTS</arm_group_label>
    <arm_group_label>PAH PATIENTS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adults (age &gt; 18 years old)&#xD;
&#xD;
          -  who give their informed consent for the protocol&#xD;
&#xD;
          -  with either CTEPH referred to our insitution for pulmonary arterial endarterectomy.&#xD;
             CTEPH is defined by invasive mean pulmonary arterial pressure ≥ 25mmHg at rest,&#xD;
             secondary to chronic pulmonary embolism confirmed by computed tomographic (CT)&#xD;
             angiography and/or ventilation/perfusion scan, according to the lastest guidelines&#xD;
&#xD;
          -  Or with PAH referred to our institution for lung transplant. PAH is defined according&#xD;
             to the latest guidelines by an invasive mean pulmonary arterial pressure ≥ 25mmHg,&#xD;
             secondary to idiopathic, familial, drug or toxin, or connective tissue disease&#xD;
             etiology.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnant women&#xD;
&#xD;
          -  children&#xD;
&#xD;
          -  congenital heart diseases&#xD;
&#xD;
          -  contraindications for MRI such as metallic foreign bodies or devices, claustrophobia&#xD;
&#xD;
          -  contraindication for surgery&#xD;
&#xD;
          -  patients requiring preoperative mechanical assistance such as extracorporeal membrane&#xD;
             oxygenation&#xD;
&#xD;
          -  patients with pulmonary arterial sarcoma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>LILIA LAMRANI</last_name>
    <phone>01.40.94.25.54</phone>
    <phone_ext>33</phone_ext>
    <email>l.lamrani@ccml.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>OLAF MERCIER</last_name>
    <phone>01.40.94.86.95</phone>
    <email>o.mercier@ccml.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hopital Marie Lannelongue</name>
      <address>
        <city>Le Plessis-Robinson</city>
        <zip>92350</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 28, 2017</study_first_submitted>
  <study_first_submitted_qc>June 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2017</study_first_posted>
  <last_update_submitted>January 21, 2020</last_update_submitted>
  <last_update_submitted_qc>January 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

